A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy

Inclusion criteria

• Age 18~85 years old (including boundary value), male or female.
• Body mass index < 35 kg/m2.
• Understand the study procedures and methods, voluntarily participate in this trial, and sign the informed consent form in writing.
• Female subjects of childbearing potential must have a serum pregnancy test prior to the first dose with a negative result and must be non-lactating during the study.
• Female subjects of childbearing potential and male subjects whose partners are women of childbearing potential must agree to refrain from donating sperm/eggs from the time of signing the informed consent form until 3 months after the last dose of the trial drug, and comply with the relevant contraceptive requirements.

Exclusion criteria

• Known or suspected infiltration, hereditary, or storage disorder that can cause myocardial hypertrophy.
• Paroxysmal atrial flutter or atrial fibrillation with clinical symptoms at screening.
• History of syncope or sustained ventricular tachycardia within 6 months prior to screening.
• Those who have participated in the clinical trial of any drug or medical device within 3 months before screening.
• Other conditions that the investigator considers the subject to be unsuitable for participating in this trial.